Drug Profile
NBI 921352
Alternative Names: NBI-921352; XEN 901Latest Information Update: 04 Dec 2023
Price :
$50
*
At a glance
- Originator Xenon Pharmaceuticals
- Developer Neurocrine Biosciences; Xenon Pharmaceuticals
- Class Antiepileptic drugs; Small molecules
- Mechanism of Action Nav1.6 voltage-gated sodium channel inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Epilepsy
- Discontinued Dravet syndrome; Seizures
Most Recent Events
- 04 Dec 2023 Discontinued - Phase-II for Seizures (Adjunctive treatment) in Czech Republic, Spain, Australia, Belgium, France, Italy, United Kingdom (PO) (Xenon pharmaceuticals pipeline, December 2023)
- 21 Aug 2023 Neurocrine Biosciences completes phase-II trial in Seizures (Adjunctive treatment) in United Kingdom, Hungary, Australia, Belgium, Czech Republic, France, Italy, and Spain (PO) (NCT05159908)
- 09 Aug 2023 Neurocrine Biosciences has completed enrolment in phase-II trial in Seizures (Adjunctive treatment) in Hungary, United Kingdom, Spain, Czech Republic, Italy, Belgium, France and Australia (PO) (EudraCT 2021-001433-39) (NCT05159908)